A
Alcista
Alcista · 25%ANL
$2.06
Precio del escenario
$10.280
+0.080 (+0.78%)Al cierre
Loading chart…
- Máximo
- 10.680
- Apertura
- 10.200
- Precio medio ponderado por volumen
- 10.39
- Volumen
- 44.56K
- Capitalización
- 136.89M
- Mínimo
- 10.200
- Importe
- 462.82K
- EV/EBITDA, TTM
- -240.66
Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment.
Análisis de IA of Adlai Nortye Group Ltd (ANL)
MantenerAdlai Nortye Ltd (ANL) is currently a hold. The stock is trading at $10.58 with a year-to-date change of +666.67%, but the RSI is low at 32.708, indicating potential oversold conditions. Analysts project a price target of $49 from Lucid Capital, suggesting a potential upside of 363% from the current price. However, the company has a negative EPS forecast of -0.54 for Q4 2024 and a concerning net margin of -40.87% for Q2 2026, which raises risks for long-term investors.
Métricas de valoración
El PER previsto actual de Adlai Nortye Group Ltd (ANL) es 0.00, frente a su media de 5 años de -4.27.
Escenarios de precio de Alphio AI para ANL
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ANL en cartera
Cronología de eventos
Noticias
9.009-08NASDAQ.COMAdlai Nortye Initiates Global Phase I Trial for AN4035
8.509-08NewsfilterFirst-in-Class CEACAM5-Targeting ADC Clinical Trial Initiated
- 9.508-14Newsfilter
Adlai Nortye Reports H1 2026 Financial Results and Clinical Updates
2.007-16NASDAQ.COMBiotech Stocks Surge Amid Positive Developments
9.507-07NASDAQ.COMInnovative Eyewear Reports Significant Q2 Sales Growth
Preguntas frecuentes sobre ANL, respondidas por Alphio AI
Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment. It operates in the Healthcare sector.
Adlai Nortye Ltd (ANL) is currently a hold. The stock is trading at $10.58 with a year-to-date change of +666.67%, but the RSI is low at 32.708, indicating potential oversold conditions. Analysts project a price target of $49 from Lucid Capital, suggesting a potential upside of 363% from the current price. However, the company has a negative EPS forecast of -0.54 for Q4 2024 and a concerning net margin of -40.87% for Q2 2026, which raises risks for long-term investors.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.